Literature DB >> 32259588

Rationale and design of a randomized study comparing Motivational Interviewing to Support Oral Anticoagulation adherence versus usual care in patients with nonvalvular atrial fibrillation: The MISOAC-AF trial.

A Samaras1, A Kartas1, D Vasdeki1, G Dividis1, E Forozidou1, G Fotos1, E Kotsi1, E Paschou1, P Tsoukra1, I Goulas1, H Karvounis1, G Giannakoulas1, A Tzikas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32259588     DOI： 10.1016/j.hjc.2020.02.007

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN： 1109-9666


× No keyword cloud information.
  3 in total

1.  Prognostic significance of diabetes mellitus in patients with atrial fibrillation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Athanasios Samaras; Ioannis Vouloagkas; Eleni Vrana; Dimitrios V Moysidis; Evangelos Akrivos; Georgios Kotzampasis; Amalia Baroutidou; Anastasios Papanastasiou; Evangelos Liampas; Michail Botis; Efstratios Karagiannidis; Nikolaos Stalikas; Haralambos Karvounis; Apostolos Tzikas; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2021-02-11       Impact factor: 9.951

2.  Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation.

Authors:  Athanasios Samaras; Eleni Vrana; Anastasios Kartas; Dimitrios V Moysidis; Andreas S Papazoglou; Ioannis Doundoulakis; George Fotos; Georgios Rampidis; Dimitrios G Tsalikakis; Georgios Efthimiadis; Haralambos Karvounis; Apostolos Tzikas; George Giannakoulas
Journal:  BMC Cardiovasc Disord       Date:  2021-09-18       Impact factor: 2.298

3.  Sex-Related Differences in Clinical Outcomes in Patients with Atrial Fibrillation and Coronary Artery Disease: A Sub-Study of the MISOAC-AF Randomized Controlled Trial.

Authors:  Alexandra Bekiaridou; Athanasios Samaras; Anastasios Kartas; Andreas S Papazoglou; Dimitrios V Moysidis; Vasiliki Patsiou; Stefanos Zafeiropoulos; Antonios Ziakas; George Giannakoulas; Apostolos Tzikas
Journal:  J Clin Med       Date:  2022-10-01       Impact factor: 4.964
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.